1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Human Insulin Market, By Product Type
5.1 Introduction
5.2 Traditional Human Insulin
5.2.1 Short-Acting Biologics
5.2.2 Intermediate-Acting Biologics
5.2.3 Premixed Biologics
5.3 Insulin Analogs and Biosimilars
5.3.1 Rapid-Acting Biosimilars
5.3.2 Long-Acting Biosimilars
5.3.3 Premix Biosimilars
5.4 Other Product Types
6 Global Human Insulin Market, By Diabetes Type
6.1 Introduction
6.2 Type I Diabetes
6.3 Type II Diabetes
6.4 Other Diabetes Types
7 Global Human Insulin Market, By Distribution Channel
7.1 Introduction
7.2 Retail & Online Pharmacies
7.3 Hospitals Pharmacies
7.4 Other Distribution Channels
8 Global Human Insulin Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Eli Lilly and Company
10.2 Novo Nordisk A/S
10.3 Tonghua Dongbao Pharmaceutical Co. Ltd.
10.4 Julphar
10.5 Biocon Ltd
10.6 Sanofi
10.7 United Laboratories International Holdings Limited
10.8 Pfizer, Inc.
10.9 Boehringer Ingelheim International GmbH
10.10 Wockhardt
10.11 Bristol-Myers Squibb Company.
10.12 Oramed Pharmaceuticals, Inc.
10.13 GlaxoSmithKline Plc.
10.14 Gan & Lee Pharmaceuticals Co Ltd.
10.15 Ypsomed AG
10.16 Shanghai Fosun Pharmaceutical Co., Ltd
List of Tables
Table 1 Global Human Insulin Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 3 Global Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 4 Global Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 5 Global Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 6 Global Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 7 Global Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 8 Global Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 9 Global Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 10 Global Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 11 Global Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 12 Global Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 13 Global Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 14 Global Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 15 Global Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 16 Global Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 17 Global Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 18 Global Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 19 Global Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Table 20 North America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
Table 21 North America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 22 North America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 23 North America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 24 North America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 25 North America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 26 North America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 27 North America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 28 North America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 29 North America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 30 North America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 31 North America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 32 North America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 33 North America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 34 North America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 35 North America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 36 North America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 37 North America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 38 North America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Table 39 Europe Human Insulin Market Outlook, By Country (2020-2028) ($MN)
Table 40 Europe Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 41 Europe Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 42 Europe Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 43 Europe Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 44 Europe Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 45 Europe Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 46 Europe Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 47 Europe Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 48 Europe Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 49 Europe Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 50 Europe Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 51 Europe Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 52 Europe Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 53 Europe Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 54 Europe Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 55 Europe Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 56 Europe Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 57 Europe Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Table 58 Asia Pacific Human Insulin Market Outlook, By Country (2020-2028) ($MN)
Table 59 Asia Pacific Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 60 Asia Pacific Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 61 Asia Pacific Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 62 Asia Pacific Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 63 Asia Pacific Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 64 Asia Pacific Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 65 Asia Pacific Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 66 Asia Pacific Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 67 Asia Pacific Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 68 Asia Pacific Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 69 Asia Pacific Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 70 Asia Pacific Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 71 Asia Pacific Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 72 Asia Pacific Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 73 Asia Pacific Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 74 Asia Pacific Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 75 Asia Pacific Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 76 Asia Pacific Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Table 77 South America Human Insulin Market Outlook, By Country (2020-2028) ($MN)
Table 78 South America Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 79 South America Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 80 South America Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 81 South America Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 82 South America Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 83 South America Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 84 South America Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 85 South America Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 86 South America Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 87 South America Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 88 South America Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 89 South America Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 90 South America Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 91 South America Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 92 South America Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 93 South America Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 94 South America Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 95 South America Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Table 96 Middle East & Africa Human Insulin Market Outlook, By Country (2020-2028) ($MN)
Table 97 Middle East & Africa Human Insulin Market Outlook, By Product Type (2020-2028) ($MN)
Table 98 Middle East & Africa Human Insulin Market Outlook, By Traditional Human Insulin (2020-2028) ($MN)
Table 99 Middle East & Africa Human Insulin Market Outlook, By Short-Acting Biologics (2020-2028) ($MN)
Table 100 Middle East & Africa Human Insulin Market Outlook, By Intermediate-Acting Biologics (2020-2028) ($MN)
Table 101 Middle East & Africa Human Insulin Market Outlook, By Premixed Biologics (2020-2028) ($MN)
Table 102 Middle East & Africa Human Insulin Market Outlook, By Insulin Analogs and Biosimilars (2020-2028) ($MN)
Table 103 Middle East & Africa Human Insulin Market Outlook, By Rapid-Acting Biosimilars (2020-2028) ($MN)
Table 104 Middle East & Africa Human Insulin Market Outlook, By Long-Acting Biosimilars (2020-2028) ($MN)
Table 105 Middle East & Africa Human Insulin Market Outlook, By Premix Biosimilars (2020-2028) ($MN)
Table 106 Middle East & Africa Human Insulin Market Outlook, By Other Product Types (2020-2028) ($MN)
Table 107 Middle East & Africa Human Insulin Market Outlook, By Diabetes Type (2020-2028) ($MN)
Table 108 Middle East & Africa Human Insulin Market Outlook, By Type I Diabetes (2020-2028) ($MN)
Table 109 Middle East & Africa Human Insulin Market Outlook, By Type II Diabetes (2020-2028) ($MN)
Table 110 Middle East & Africa Human Insulin Market Outlook, By Other Diabetes Types (2020-2028) ($MN)
Table 111 Middle East & Africa Human Insulin Market Outlook, By Distribution Channel (2020-2028) ($MN)
Table 112 Middle East & Africa Human Insulin Market Outlook, By Retail & Online Pharmacies (2020-2028) ($MN)
Table 113 Middle East & Africa Human Insulin Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
Table 114 Middle East & Africa Human Insulin Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
| ※参考情報 ヒトインスリンとは、体内で血糖値を調整する重要なホルモンの一つです。インスリンは膵臓のβ細胞で生成され、食事に含まれる糖分を細胞に取り込み、エネルギーとして利用する手助けをします。不足すると血糖値が上昇し、糖尿病などの疾患を引き起こすことがあります。ここではヒトインスリンの定義、種類、用途、関連技術について詳しく説明いたします。 ヒトインスリンの種類としては、主に「速効型インスリン」、「中間型インスリン」、「持続型インスリン」の三つに分けられます。速効型インスリンは、食事の直前または直後に投与されるもので、血糖値を短時間で下げる効果があります。中間型インスリンは、効果が持続する時間が長く、食事の間隔に合わせて投与されることが一般的です。持続型インスリンは、24時間以上にわたり血糖を安定させるために設計されており、生活リズムに合わせた使用が可能です。このように、患者のニーズに応じて様々な種類のインスリンが存在します。 ヒトインスリンの用途は多岐にわたりますが、主に糖尿病治療に用いられます。1型糖尿病患者は、膵臓がインスリンを適切に分泌できないため、外部からインスリンを補充する必要があります。また、2型糖尿病患者の中でも、食事療法や運動療法だけでは血糖コントロールが難しい場合には、インスリン治療が考慮されます。このように、インスリンは糖尿病管理において欠かせない治療法の一部となっています。 ヒトインスリンを利用した治療は、いくつかの関連技術によってさらに進化しています。まず、持続的インスリン注入装置（インスリンポンプ）があります。この装置は患者が希望する量のインスリンを持続的に自動投与するもので、患者の血糖管理を容易にします。また、血糖値を連続的にモニタリングするデバイスと組み合わせることで、より精密な治療が可能になります。 さらに、アプリケーションやクラウドサービスを利用したデータ管理が普及しています。これにより、患者は自分の血糖値、食事、インスリン投与量を記録し、医師との情報共有がスムーズになります。このようなデジタルツールやテクノロジーは、患者自身が自分の健康を管理する手助けをしており、糖尿病治療における重要なサポートとなっています。 ヒトインスリンは、現在では遺伝子組換え技術によって生産されることが多くなっています。この方法により、純度の高いインスリンを大量に効率よく製造することが可能となり、製造コストの削減にも寄与しています。また、これによりアレルギー反応や免疫反応を引き起こすリスクが少なくなり、多くの患者に安全に使用できるようになりました。 インスリンに関する研究は進んでおり、新しい製剤の開発も続いています。例えば、超速効型インスリンや持続型インスリンの改良版が開発され、より効率的な血糖管理が可能となることが期待されています。また、インスリン抵抗性に対する新たな治療法の研究も進行中であり、糖尿病治療の選択肢が増えていくことが見込まれています。 このように、ヒトインスリンは糖尿病治療に不可欠なホルモンであり、さまざまな種類と関連技術が展開されています。今後も研究の進展によって、より効果的な療法が提供されることが期待され、それにより多くの患者が日常生活をより快適に送ることができるようになるでしょう。ヒトインスリンの理解を深めることで、患者自身がより良い健康管理を行えるスキルを身につけることが大切です。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
